Anavex Life Sciences Corp. (AVXL)

NASDAQ: AVXL · Real-Time Price · USD

3.380

+0.040 (1.20%)

Aug 10, 2026, 2:11 PM EDT - Market open

Anavex Life Sciences Financials Overview

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Operating Income	-38.57	-51.41	-52.88	-55.76	-50.99	-42
Net Income	-11.02	-46.38	-43	-47.51	-47.62	-37.64
Earnings Per Share	-0.39	-0.54	-0.52	-0.60	-0.62	-0.54
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Cash & Investments	127.42	102.58	132.19	151.02	149.16	152.11
Total Debt	0	0	0	0	0	0
Net Cash (Debt)	127.42	102.58	132.19	151.02	149.16	152.11
Net Cash Growth	10.06%	-22.40%	-12.47%	1.25%	-1.94%	420.04%
Net Cash Per Share	1.44	1.20	1.58	1.89	1.94	2.18

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Operating Cash Flow	-34.08	-39.04	-30.81	-27.79	-24.24	-30.38
Free Cash Flow	-34.08	-39.04	-30.81	-27.79	-24.24	-30.38
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 10, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Forward PE	-	10.73	-	-	-	-